近年来,以胰高糖素样肽-l(Glucagon like peptide-1,GLP-1)研究为基础的糖尿病新药成为糖尿病药物治疗领域的最大热点。与经典降糖药物相比,该类新药更少的低血糖发生率、降低空腹及餐后胰高血糖素、减轻体重、并在动物实验中证实能增加胰岛β细胞数量等诸多优点备受关注[4]。从糖尿病发病机制新学说-肠道学说的角度来认识和理解GLP-l在糖尿病发生发展中的作用可以使 In recent years, the new diabetes drugs based on the study of Glucagon-like peptide-1 (GLP-1) have become the hot spots in the field of diabetes drug treatment. Much attention has been paid to the advantages of fewer hypoglycaemic agents, lower fasting and postprandial glucagon, weight loss, and more animal experiments demonstrating increased islet β-cell mass compared to classical hypoglycemic agents [4]. Understanding and understanding the role of GLP-1 in the development of diabetes from the new theory of pathogenesis of diabetes mellitus